Satellos Bioscience (MSCL) Stock Overview
A clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MSCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeSatellos Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$9.80 |
| 52 Week High | CA$18.98 |
| 52 Week Low | CA$6.24 |
| Beta | 1.19 |
| 1 Month Change | 24.05% |
| 3 Month Change | -38.94% |
| 1 Year Change | 25.64% |
| 3 Year Change | 48.48% |
| 5 Year Change | n/a |
| Change since IPO | -54.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| MSCL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -8.8% | -3.7% | 1.0% |
| 1Y | 25.6% | 22.8% | 34.0% |
Return vs Industry: MSCL underperformed the Canadian Biotechs industry which returned 29.9% over the past year.
Return vs Market: MSCL underperformed the Canadian Market which returned 34.5% over the past year.
Price Volatility
| MSCL volatility | |
|---|---|
| MSCL Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: MSCL's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: MSCL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 20 | Frank Gleeson | satellos.com |
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.
Satellos Bioscience Inc. Fundamentals Summary
| MSCL fundamental statistics | |
|---|---|
| Market cap | CA$217.69m |
| Earnings (TTM) | -CA$33.96m |
| Revenue (TTM) | n/a |
Is MSCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSCL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.51m |
| Gross Profit | -US$1.51m |
| Other Expenses | US$23.37m |
| Earnings | -US$24.87m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MSCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 20:26 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Satellos Bioscience Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |